Exact Sciences Q4 Revenues Slide 40 Percent, Cologuard Trial Progressing | GenomeWeb

The story has been updated to include comments from company officials during a conference call.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported a 40 percent drop year over year in fourth-quarter revenues, though its CEO said that the clinical trial for its colorectal cancer screening test "remains on track."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.